Concepedia

Prevention of cardiac allograft vasculopathy – A new possible indication for SGLT-2 inhibitors?

Petra Grubić Rotkvić, Maja Cigrovski Berković, Luka Rotkvić, Nikola Bulj

Medical Hypotheses · 2020 · 12 citations · 16 references

DOI

Concepts

References

16

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

, , +15

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text

, , +17

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi et al. · New England Journal of Medicine · 2019 · 6.9K citations · Full text

, , +14

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text

, , +17

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

Bo-Wen Lin, Nobutaka Koibuchi, Yu Hasegawa et al. · Cardiovascular Diabetology · 2014 · 422 citations · Full text

, , +17